| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers N > Headlines for Neurochem Inc. > News item |
Neurochem says preclinical studies show promising results for tramiprosate to treat Alzheimer's disease
By E. Janene Geiss
Philadelphia, May 30 - Neurochem Inc. said Tuesday that preclinical development of its Alzheimer's disease drug candidate tramiprosate (3-amino-1-propanesulfonic acid) shows promising results in mice with brain amyloidosis.
The study of tramiprosate, known as Alzhemed, shows its amyloid binding and neuroprotective characteristics and provides evidence for the potential disease-modifying effect of this product candidate to slow or arrest the progression of Alzheimer's disease, according to a company news release.
Results of the study will be published in Neurobiology of Aging, one of the world's leading peer-reviewed medical journals in the fields of gerontology and neuroscience, officials said.
Some of the study's findings show that that tramiprosate binds preferentially to soluble A(B) peptide and maintains A(B) in a non-fibrillar form. Tramiprosate also was shown to decrease by 38% A(B)42-induced cell death in primary rat neuronal cell cultures, and treatment with the drug candidate in a mouse model of brain amyloidosis resulted in a dose-dependent reduction of more than 60% of A(B) levels in plasma.
There were significant decreases in brain levels of both soluble A(B)40 and insoluble A(B)40, officials said.
Corresponding decreases of 25% and 22% were observed for the soluble and insoluble fractions of A(B)42 peptide, respectively, officials added.
Tramiprosate crosses the blood-brain-barrier to exert its activity with low toxicity in various animal species that were tested, officials said.
Neurochem is a Laval, Quebec, biopharmaceutical company.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.